Verastem Inc (VSTM)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $970.31M
Last updated: Nov 17, 2026 at 4:35 PM ET
Verastem Inc (VSTM) Statistics
Verastem (VSTM) has a market cap of $970.31M and an enterprise value of $916.94M. Revenue grew 2847.28% over the last 12 months from the 12 months before. Its share count is up 38.38% from a year earlier.
Total Valuation
Enterprise value is 5.50% below the market cap, as cash exceeds debt.
| Market Cap | $970.31M |
|---|---|
| Enterprise Value | $916.94M |
| Latest price (Nov 17, 2026) | $7.41 |
Key Dates
The next earnings report is expected on Mar 2, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Mar 2, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 5, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 7.5x and 74.3x. Its year-end P/S ranged from 3.9x to 179.7x from 2018 to 2025.
| P/S Ratio | 7.5x |
|---|---|
| Forward P/S | 9.0x |
| P/B Ratio | 74.3x |
Price Statistics
The stock is down 1.92% over 52 weeks and trades 12.41% below its 50-day average.
| Beta (1Y) | 1.06 |
|---|---|
| 52-Week Change | -1.92% |
| 1-Month Change | -14.04% |
| 3-Month Change | +1.58% |
| 6-Month Change | +78.55% |
| 5-Year Change | -68.76% |
| 10-Year Change | -35.03% |
| Total Return (1Y) | -1.92% |
| Total Return (3Y CAGR) | +5.39% |
| Total Return (5Y CAGR) | -27.07% |
| Return vs SPY (1Y) | -31.62% |
| Max Drawdown (1Y) | -67.58% |
| Max Drawdown (3Y) | -84.36% |
| Sharpe Ratio (1Y) | -0.32 |
| Correlation with SPY (1Y) | 0.21 |
| 50-Day Average | $8.46 |
| 200-Day Average | $6.31 |
| 52-Week Range | $3.43 to $10.82 |
| RSI (14 Days) | 35.1 |
| Average Volume (20 Days) | 3.18M |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 1.93x current liabilities, and total debt is 11.82x shareholder equity.
| Current Ratio | 1.93x |
|---|---|
| Quick Ratio | 1.91x |
| Debt / Equity | 11.82x |
| Interest Coverage | -132.21x |
Returns and Efficiency
Return on invested capital is -110.39% over the last 12 months, against a 5-year average of -89.92%.
| Return on Equity (ROE) | -1771.14% |
|---|---|
| Return on Assets (ROA) | -77.91% |
| Return on Invested Capital (ROIC) | -110.39% |
| Return on Capital Employed (ROCE) | -143.29% |
| ROA (5Y Average) | -83.04% |
| ROIC (5Y Average) | -89.92% |
| Asset Turnover | 0.49x |
| Inventory Turnover | 5.51x |
| Receivables Turnover | 5.18x |
| Cash Conversion Cycle | -408 days |
Scores
VSTM has an Altman Z-Score of -7.60, in the distress zone below 1.81, and a Piotroski F-Score of 5 of 9, in the average band of 3 to 7.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | -7.60 |
|---|---|
| Altman Z Zone | Distress |
| Piotroski F-Score | 5 of 9 |
| Piotroski Strength | Average |
Income Statement
Revenue was $100.30M over the last 12 months.
| Revenue | $100.30M |
|---|---|
| Revenue Growth (YoY) | +2847.28% |
| Gross Profit | $87.48M |
| Operating Income | -$194.31M |
| Pretax Income | -$354.64M |
| Net Income | -$178.90M |
| EBITDA | -$180.09M |
| EBIT | -$180.99M |
| Reported EPS (TTM) | -$1.98 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 4.40% of the $229.64M in total assets.
| Cash and Equivalents | $172.80M |
|---|---|
| Total Debt | $119.43M |
| Net Cash | $53.37M |
| Net Cash Per Share | $0.53 |
| Working Capital | $96.05M |
| Shareholder Equity | $10.10M |
| Book Value Per Share | $0.10 |
| Tangible Book Value | -$5.49M |
| Total Assets | $229.64M |
| Total Liabilities | $219.54M |
Balance sheet as of Sep 30, 2026.
Cash Flow
| Operating Cash Flow | -$159.57M |
|---|---|
| FCF Per Share | -$1.32 |
| Depreciation and Amortization | $901.00K |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -193.73%.
| Gross Margin | 87.23% |
|---|---|
| Operating Margin | -193.73% |
| Pretax Margin | -353.60% |
| Net Margin | -178.38% |
| EBITDA Margin | -179.56% |
| EBIT Margin | -180.46% |
Growth
Revenue grew 128.36% a year over 3 years.
| Revenue Growth (3Y CAGR) | +128.36% |
|---|---|
| Revenue Growth (5Y CAGR) | -18.97% |
| Book Value Per Share Growth (2Y CAGR) | -43.39% |
| Tangible Book Per Share Growth (2Y CAGR) | -52.21% |
Dividends and Yields
VSTM does not pay a dividend.
| Buyback Yield | -16.75% |
|---|---|
| Shareholder Yield | -16.75% |
Stock Splits
The last split was a 1-for-12 reverse split on Jun 1, 2023.
| Last Split Date | Jun 1, 2023 |
|---|---|
| Split Type | Reverse split |
| Split Ratio | 1:12 |
Peer Position
Against 7 similar companies, VSTM has the 3rd highest P/S.
P/S RatioPeer median 3.8x
ROICPeer median -65.05%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median -18.95%
| P/S Ratio | 7.5x vs 3.8x median |
|---|---|
| ROIC | -110.39% vs -65.05% median |
| Revenue Growth (Trailing 4 Quarters, YoY) | +2847.28% vs -18.95% median |
Analyst Forecast
Consensus estimates put revenue growth at 116.29% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | +116.29% |
|---|
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About VSTM
What is VSTM's market cap?
Verastem has a market cap of $970.31M. Its enterprise value, which adds debt and subtracts cash, is $916.94M.
How many shares of VSTM are outstanding?
Verastem has 101.24M shares outstanding. The count is up 38.38% from a year earlier.
Does VSTM pay a dividend?
No. Verastem does not pay a dividend.
How much debt does VSTM have?
Verastem has $119.43M of total debt and $172.80M of cash and equivalents, a net cash position of $53.37M.
VSTM pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors